Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Branko %C5%A0tublar) .

1 - 10 / 164
Na začetekNa prejšnjo stran12345678910Na naslednjo stranNa konec
1.
Digital ischemic events related to gemcitabine : report of two cases and a systematic review
Cvetka Grašič-Kuhar, Tanja Mesti, Branko Zakotnik, 2010, izvirni znanstveni članek

Objavljeno v DiRROS: 15.03.2024; Ogledov: 66; Prenosov: 26
.pdf Celotno besedilo (621,57 KB)

2.
Preoperative concomitant chemoradiotherapy in esophageal cancer
Boštjan Šeruga, Mihael Sok, Janez Eržen, Jože Jerman, Boris Jančar, Branko Zakotnik, 2006, izvirni znanstveni članek

Povzetek: Background. Currently primary treatment options for esophageal cancer are surgery only or concomitant chemoradiotherapy (CRT) and the long-term survivalof patients with locally advanced disease is rare. Preoperative concomitant CRT seems to be beneficial, mostly in patients who achieve a complete pathologic response (pCR) after CRT. In this retrospective analysis the efficiency and toxicity of preoperative CRT in patients with locally advanced esophageal cancer was analysed as well as the influence of pCR on thesuraival. Patients and metkods From 1996 to 2002 41 patients with locoregionally confined esophageal cancerwere treated with cisplatin 75 mgžm2 and 5-FU 1000 mgžm2 as 4 day contonuous infusion starting on days 1. and 22. with concorrtitant radiotherapy 4500 cGy, 200-300 cGyžday. Esophagectomy followed 4-5 weeks after radiotherapy. After the surgery patients were followed-up regularly at 3-6 months intervals. Results. The pCR was achieved in 26.8% of patients. The overall median survival time was 18 months for all patients, 21.2 months for patients who achieved pCR and 16 months in those with residual disease (p= 0,79). Postoperative mortality rate was 22%. The median dose intensity for cisplatin was 92% and for 5-FU 71.5 of the planned dose. Disease recurred most often locoregionally (31.7%) and the overall recurrence rate was 43.9. Conclusion. Modern radiation techniques and the adequate dose intensity could further improve the locoregional control. The selection of patients without comorbid conditions and without already present distant metastases is essential for this combined treatment approach.
Objavljeno v DiRROS: 15.02.2024; Ogledov: 101; Prenosov: 25
.pdf Celotno besedilo (123,83 KB)

3.
Environment and breast cancer - the role of xenooestrogens in breast cancer
Andrej Plesničar, Branko Družina, Viljem Kovač, Božo Kralj, 2002, izvirni znanstveni članek

Povzetek: The survival rate of breast cancer patients has not changed much in the last few decades in developed countries. In order to improve the efficacy of breast cancer prevention and treatment, the role of xenooestrogens in the mechanisms of its development has been evaluated. These industrial chemical bear little structural resemblance to each other and bind to the oestrogen receptors of exposed cells and/or trigger oestrogenic responses in laboratory test systems. Exposure to xenooestrogens has been regarded as a risk factor for carcinogenesis and a preventable cause of breast carcinoma. Several epidemiological and experimental studies in in vivo and in vitro conditions of the influence of xenooestrogens on the occurrence of breast cancer have been conducted in the last decades and have shown ambiguous results. No increase of breast carcinoma incidence could be found in women who were exposed to relatively high concentrations of xenooestrogens for extended periods and small quantities of these compounds that are present in the environment probably cannot act as etiological agents for the occurence of this disease. A multi step approach is suggested regarding the sequence of studies and measures that should be taken to further assess the importance of xenooestrogens on breast cancer carcinogenesis.
Ključne besede: dojka, ksenoestrogeni, novotvorbe
Objavljeno v DiRROS: 31.01.2024; Ogledov: 106; Prenosov: 26
.pdf Celotno besedilo (96,95 KB)

4.
Indium-111-DTPA-octreotide scintigraphy in patients with carcinoid tumor
Stanko Težak, Rajko Ostojić, Zdravko Perković, Nadan Rustemović, Nikica Car, Branko Papa, Mirjana Poropat, Damir Dodig, 1999, izvirni znanstveni članek

Povzetek: Background. The aim of the study was the evaluation of clinical utility and comparison of 111 In-DTPA- octreotide receptor scintigraphy (SRS) with conventional imaging modalities (CIM) in the detection of carcinoid tumor. Patients and methods. Fourteen patients with pathohistologically proven diagnosis of carcinoid tumor and one patient with clinical suspicion of carcinoid tumor were investigated by SRS. SRS was performed for localization of primary tumor, recurrence or estimation of spread of the disease after CIM had been completed. Whole body scans and single photon emission computed tomography (SPECT) were acquired 6 and 24 h after the application of radiopharmaceutical. The intensity of nonspecific radiopharmaceutical uptake in the bowel was assessed semiquantitatively by a score using whole body scans. Results. The evaluation was done for patients and for tumor sites. The sensitivity, specificity, and positive and negative predictive values for patient evaluation were 89 %,100 %,100 % and 80 %, respectively for both CIM and SRS, whereas for tumor sites, these parameters were 69 % 100 %,100 % and 82 % for CIM, and 88%,100%,100% and 92 % for SRS. Intensity score of nonspecific 111In-octreotide bowel accumulation was 0.92 and 2.01 for 6 and 24h scans respectively (p < 0.01). Conclusion. 111In-octreotide scintigraphy should be included in the diagnostic algorithm for the patients with clinical suspicion of carcinoid and for the assessment of patients with proven carcinoid tumor.
Objavljeno v DiRROS: 22.01.2024; Ogledov: 141; Prenosov: 31
.pdf Celotno besedilo (554,71 KB)

5.
6.
7.
Early glottic cancer : the influence of primary therapy on ultimate organ preservation
Hotimir Lešničar, Alojz Šmid, Branko Zakotnik, 1997, izvirni znanstveni članek

Objavljeno v DiRROS: 16.01.2024; Ogledov: 148; Prenosov: 33
.pdf Celotno besedilo (215,84 KB)

8.
9.
Differential diagnosis between bone metastases and osteomalacia
Branko Zakotnik, Simona Borštnar, Tadeja Movrin, Boris Jančar, Andreja Zidar, 1996, izvirni znanstveni članek

Povzetek: In oncology the diagnosis of skeletal metastases is a frequent one, in infact so frequent that other diagnoses such as metabolic bone diseases affecting patients with cancer may be overlooked. In our report two cases of osteomalacia referred to an oncologist are presented; in both of them the diagnosis of diffuse bone metastases of unknown origin was suspected. The differential diagnosis is discussed and the importance of bone marrow biopsy using Yamshidi needle for diagnosis of metabolic bone disease is emphasized.
Objavljeno v DiRROS: 16.01.2024; Ogledov: 132; Prenosov: 33
.pdf Celotno besedilo (318,84 KB)

10.
Prognostic value of staging laparotomy in supradiaphragmatic clinical stage I and II Hodgkin's disease
Marjeta Vovk, Tatjana Šumi-Križnik, Marija Jenko-Fidler, Gabrijela Petrič-Grabnar, Marinka Kremžar, Janez Novak, Mojca Senčar, Branko Zakotnik, Alenka Vodnik-Cerar, Branimir Jakšić, 1996, izvirni znanstveni članek

Povzetek: In the period 1974-1989, 219 patients with supradiaphragmatic clinical stage I and II Hodgkin's disease were treated at the Institute of Oncology in Ljubljana; of these 95 (43%) patients underwent staging laparotomy. Of laparotomized patients, those with pathological stage III-IV, and of non-laparotomized, those with unfavorable prognostic factors (B-symptoms, bulky mediastinum) received chemotherapy: the remaining patients were treated by irradiation. No statistically significant difference in the survival and disease-free survival between laparotomized and nonlaparotomized patients could be found.
Objavljeno v DiRROS: 16.01.2024; Ogledov: 149; Prenosov: 42
.pdf Celotno besedilo (364,35 KB)

Iskanje izvedeno v 0.32 sek.
Na vrh